Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Tracon Pharmaceuticals, Inc. (TCON)
Sector: Healthcare; Industry: Biotechnology

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2022-01-28 Opaleye Management Inc. 10%-Owner Buy 500 $2.20 $1,100 No
2022-01-24 Opaleye Management Inc. 10%-Owner Buy 52,363 $2.15 $112,414 No
2022-01-20 Opaleye Management Inc. 10%-Owner Buy 45,000 $2.25 $101,032 No
2021-12-29 Opaleye Management Inc. 10%-Owner Buy 52,325 $2.51 $131,362 No
2021-12-15 Opaleye Management Inc. 10%-Owner Buy 21,964 $2.43 $53,287 No
2021-12-14 Opaleye Management Inc. 10%-Owner Buy 57,204 $2.56 $146,498 No
2021-12-06 Opaleye Management Inc. 10%-Owner Buy 112,007 $2.29 $256,385 No
2021-12-02 Opaleye Management Inc. 10%-Owner Buy 60,500 $2.39 $144,820 No
2021-11-19 THEUER CHARLES President and CEO Buy 4,181 $2.83 $11,831 No
2021-11-05 THEUER CHARLES President and CEO Buy 4,000 $3.41 $13,655 No
2021-08-13 Brown Scott B. Chief Financial Officer Buy 1,000 $3.69 $3,695 No
2021-07-26 LARUE WILLIAM R Director Buy 6,545 $3.82 $25,002 No
2021-03-08 Brown Scott B. Chief Financial Officer Buy 1,000 $8.30 $8,296 No
2021-01-27 THEUER CHARLES President and CEO Buy 11,000 $8.98 $98,771 No
2020-12-30 Ikarian Capital, LLC Member of 10% Group Buy 520,291 $9.61 $4,999,997 No
2020-12-29 WIGGINS MARK C Chief Business Officer Buy 1,000 $10.57 $10,570 No
2020-12-22 Opaleye Management Inc. 10%-Owner Buy 496,277 $8.06 $3,999,993 No
2020-11-11 Ikarian Capital, LLC Member of 10% Group Buy 34,000 $5.10 $173,269 No
2020-10-21 Opaleye Management Inc. 10%-Owner Buy 8,656 $4.40 $38,060 No
2020-10-21 THEUER CHARLES President and CEO Buy 2,000 $4.38 $8,769 No
2020-09-24 Opaleye Management Inc. 10%-Owner Buy 78,734 $4.73 $372,095 No
2020-09-23 THEUER CHARLES President and CEO Buy 5,000 $4.72 $23,599 No
2020-09-11 Ikarian Capital, LLC Member of 10% Group Buy 322,471 $3.28 $1,057,387 No
2020-09-11 Ikarian Capital, LLC Member of 10% Group Buy 322,471 $3.28 $1,057,387 No
2020-09-10 WIGGINS MARK C Chief Business Officer Buy 7,000 $4.14 $28,953 No
2020-09-09 Opaleye Management Inc. 10%-Owner Buy 56,558 $3.38 $190,902 No
2020-09-04 THEUER CHARLES President and CEO Buy 10,000 $2.58 $25,750 No
2020-09-02 Opaleye Management Inc. 10%-Owner Buy 159,800 $2.28 $363,825 No
2020-08-31 Opaleye Management Inc. 10%-Owner Buy 545,504 $1.74 $950,378 Yes
2020-08-21 THEUER CHARLES President and CEO Buy 5,325 $1.56 $8,307 No

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.

Insider Smart

Upwork Inc (UPWK) - GRETSCH GREGORY C. Director of Upwork, made a bulk buy of 500K shares right before the big gap up, which is also the largest buy of the past 12 months.